CD4 and Parkinson disease: Finally, it is important to mention that there is already some evidence showing significant therapeutic effects in animal models of PD, induced by MPTP, 6-OHDA or rotenone, when treated with therapies used in MS to block the infiltration of autoreactive CD4+ T-cells into the brain, such as Fingolimod/FTY720 (129–131).